MedTrace Logo

Study of the Effects of an Oral Nitric Oxide Supplement on Blood Pressure in Prehypertensive Adults

NCT01937754 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-09-10

No results posted yet for this study

Summary

Oral supplementation of Neo40(TM), a nitrate lozenge, will reduce blood pressure in healthy adults with clinical prehypertension.

Conditions

  • Prehypertension

Interventions

DIETARY_SUPPLEMENT

Nitric Oxide supplement

Lozenge consisting of beetroot and 75 mg caffeine

DIETARY_SUPPLEMENT

Placebo

Same form factor and flavor as test lozenge but contains no active ingredients

Sponsors & Collaborators

  • Neogenis Laboratories

    lead OTHER

Principal Investigators

  • Ernst Schwarz, MD, PhD · California Medical Institute, Cedars Sinai Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01937754 on ClinicalTrials.gov